Literature DB >> 27057455

Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer.

Sumanta K Pal1, Marcin Kortylewski2.   

Abstract

The myeloid-derived suppressor cells (MDSCs) contribute to tumor immune evasion and still remain an elusive therapeutic target. Our study identified granulocytic MDSCs accumulating in prostate cancer patients during disease progression. We demonstrate the feasibility of using STAT3siRNA-based strategy for targeting MDSCs to alleviate arginase-dependent suppression of T cell activity.

Entities:  

Keywords:  Arginase; MDSC; STAT3; TLR9; immunotherapy; myeloid-derived suppressor cells; prostate cancer

Year:  2015        PMID： 27057455      PMCID： PMC4801434          DOI： 10.1080/2162402X.2015.1078060

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Coordinated regulation of myeloid cells by tumours.

Authors:  Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Vincenzo Bronte
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

2.  CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Christine Zoglmeier; Helen Bauer; Daniel Noerenberg; Georg Wedekind; Philipp Bittner; Nadja Sandholzer; Moritz Rapp; David Anz; Stefan Endres; Carole Bourquin
Journal:  Clin Cancer Res       Date:  2011-01-13       Impact factor: 12.531

3.  TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.

Authors:  Dewan M S Hossain; Sumanta K Pal; Dayson Moreira; Priyanka Duttagupta; Qifang Zhang; Haejung Won; Jeremy Jones; Massimo D'Apuzzo; Stephen Forman; Marcin Kortylewski
Journal:  Clin Cancer Res       Date:  2015-05-12       Impact factor: 12.531

4.  TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.

Authors:  Chan Gao; Anna Kozlowska; Sergey Nechaev; Haiqing Li; Qifang Zhang; Dewan M S Hossain; Claudia M Kowolik; Peiguo Chu; Piotr Swiderski; Don J Diamond; Sumanta K Pal; Andrew Raubitschek; Marcin Kortylewski
Journal:  Cancer Res       Date:  2013-10-23       Impact factor: 12.701

Review 5.  CpG still rocks! Update on an accidental drug.

Authors:  Arthur M Krieg
Journal:  Nucleic Acid Ther       Date:  2012-02-21       Impact factor: 5.486

6.  Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.

Authors:  Stanimir Vuk-Pavlović; Peggy A Bulur; Yi Lin; Rui Qin; Carol L Szumlanski; Xinghua Zhao; Allan B Dietz
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

7.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

8.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.

Authors:  Marcin Kortylewski; Maciej Kujawski; Andreas Herrmann; Chunmei Yang; Lin Wang; Yong Liu; Rosalba Salcedo; Hua Yu
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

9.  TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.

Authors:  Dayson Moreira; Qifang Zhang; Dewan Md S Hossain; Sergey Nechaev; Haiqing Li; Claudia M Kowolik; Massimo D'Apuzzo; Stephen Forman; Jeremy Jones; Sumanta K Pal; Marcin Kortylewski
Journal:  Oncotarget       Date:  2015-07-10

10.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Authors:  Marcin Kortylewski; Piotr Swiderski; Andreas Herrmann; Lin Wang; Claudia Kowolik; Maciej Kujawski; Heehyoung Lee; Anna Scuto; Yong Liu; Chunmei Yang; Jiehui Deng; Harris S Soifer; Andrew Raubitschek; Stephen Forman; John J Rossi; Drew M Pardoll; Richard Jove; Hua Yu
Journal:  Nat Biotechnol       Date:  2009-09-13       Impact factor: 54.908
  10 in total
  3 in total

Review 1.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

2.  Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.

Authors:  Carlo Sorrentino; Zhinan Yin; Stefania Ciummo; Paola Lanuti; Li-Fan Lu; Marco Marchisio; Matteo Bellone; Emma Di Carlo
Journal:  J Immunother Cancer       Date:  2019-07-31       Impact factor: 13.751

Review 3.  Decoding the Role of Interleukin-30 in the Crosstalk Between Cancer and Myeloid Cells.

Authors:  Emma Di Carlo
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.